biomarin.com — September 2026 traffic, keywords & AI visibility

biomarin.com draws an estimated 46,100 visits a month from search engines. Effectively all of it is organic — about 46,100 visits from unpaid results. Paid search contributes only about 15 visits a month. Spread across 2,304 ranking keywords, that averages roughly 20 organic visits per keyword.

On our AI visibility scale biomarin.com earns 59 of 100 points, a grade D. It takes full marks for LLMS.txt. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10), Company profile (19/25) and Structured data (0/5).

The llms.txt on biomarin.com runs to 73 lines (3,823 characters) across 12 sections, last generated in May 2026. It introduces the site as "BioMarin Pharmaceutical". It tells AI engines the business works in Biotechnology, Biopharmaceuticals and Rare Disease Therapies. It describes 4 products, including Vimizim, Naglazyme and Kuvan. Services it lists include Clinical Trial Support, Patient Assistance and Medical Education. Technologies it mentions include Clinical data platforms and Biomanufacturing systems. The keywords it claims start with "rare diseases", "clinical trials", "biopharmaceuticals" and "genetic disorders". It gives the company type as Public.

# BioMarin Pharmaceutical

## About
BioMarin focuses on creating treatments for serious rare disorders that often lack options. They work on enzyme replacement therapies and gene-based approaches to help patients with conditions like MPS and PKU. The company runs clinical programs that bring new medicines from early research through regulatory approval and into patient hands. Their teams partner with physicians and advocacy groups to make sure therapies reach those who need them most. Over the years BioMarin has built a pipeline that targets multiple genetic disorders at once. They emphasize long-term patient follow-up and real-world data collection after launch. Manufacturing happens at dedicated facilities that meet strict quality standards for biologics. The company also invests in education so healthcare providers understand how to diagnose and manage these conditions. BioMarin maintains global reach through commercial teams in key markets while keeping headquarters in California. Their approach combines deep science with practical support programs that help families navigate treatment access. Recent work includes expanding gene therapy platforms that could change outcomes for previously untreatable diseases. They track regulatory changes closely to speed up submissions in different regions. Patient stories often guide internal decisions on which programs to prioritize. Bio

Google lists biomarin.com for about 2,304 keywords, which together bring an estimated 46,100 organic visits a month.

The latest technical audit of biomarin.com scored 0 out of 100 overall. The audit makes 12 recommendations in all, and 4 of the 4 listed first are rated high priority or critical.

BioMarin Pharmaceutical's company profile names https://www.genzyme.com, https://www.amgen.com, https://www.novartis.com and https://www.abbvie.com as competitors. Its own llms.txt adds https://www.gilead.com and https://www.regeneron.com. Outside its market, the domains ranked closest to it in our worldwide ranking are album-online.com, webcheats.com.br, canadastop100.com and vwork.de.

https://www.genzyme.com

https://www.amgen.com

https://www.novartis.com

https://www.abbvie.com

https://www.gilead.com

https://www.regeneron.com